3 Cannabis Stocks That Could Soar After Marijuana Rescheduling

U.S. marijuana rescheduling to Schedule III could materially improve after-tax profits for MSOs by allowing more expense deductions, with Curaleaf estimating about $116 million in 2025 tax savings and Green Thumb estimating up to $60 million in annual free cash flow benefit. Trulieve, Curaleaf, and Green Thumb are highlighted as likely winners, with Trulieve's $208 million tax provision offsetting nearly $92 million of pre-tax profit in 2025. The news is sector-positive and could move cannabis stocks, especially the largest MSOs, as investors price in higher profitability and expansion capacity.

Analysis

The real economic swing from Schedule III is not a one-time rerating; it is a step-change in cash conversion. Removing 280E should disproportionately reprice the highest fixed-cost operators because the incremental tax benefit drops almost directly to equity value, but the market will likely underappreciate how much it improves refinancing optionality and internal funding for store rollouts in a capital-constrained sector. That matters most for the better-capitalized MSOs, which can turn lower tax drag into share gains while weaker peers remain starved of liquidity.

The second-order winner is not just the listed operators but the broader ecosystem: cultivators, distributors, and ancillary vendors should see reduced counterparty risk as MSO balance sheets strengthen. However, that same dynamic can pressure wholesale pricing over the next 6-18 months if bigger operators use tax savings to push aggressive retail expansion and promo spend, ultimately compressing margins for smaller operators and private assets. In other words, the headline benefit is tax relief, but the durable advantage is scale.

The move looks directionally right but tactically crowded. The stocks have already responded to the policy headline, so the cleaner trade is not chasing the highest-beta name after the initial spike, but expressing relative value between profitable operators and structurally impaired balance sheets. The key risk is execution and timing: if rescheduling is delayed, challenged, or diluted into a narrower form than expected, the market can quickly unwind the forward tax savings embedded in current prices.

The contrarian angle is that federal rescheduling does not solve the core constraint on the industry: state-by-state fragmentation and limited access to banking/capital markets. That means the biggest beneficiaries may be the firms already profitable enough to self-fund growth, while the market may be overestimating how much policy alone can restore industry-wide growth. If reform becomes more symbolic than practical, the rerating could stall well before operating fundamentals do.

Key Decisions for Investors

• Long GTBIF vs. short a weaker-capitalized MSO basket for 3-6 months: prefer profitability + lower tax drag conversion over balance-sheet risk; target relative outperformance if the market starts rewarding self-funded growth.
• Buy CURLF only on pullbacks, not after headline spikes, with a 6-12 month horizon: the upside is tied to tax savings and international optionality, but the entry point matters because policy enthusiasm is already partially priced.
• Avoid chasing TCNNF after the initial move; use any strength to sell covered calls or trim exposure: Florida concentration makes it a cleaner beneficiary of tax relief, but also a higher-risk way to express the theme if reform momentum fades.
• Monitor ancillary names and state-licensed suppliers for a delayed catch-up trade over the next 1-2 quarters: improved MSO cash flow can eventually spill into capex, packaging, and services, but only after the market validates the policy change.
• Add a hedge via cannabis ETF or weak MSO short against any long basket: the main risk is a headline-driven reversal if the regulatory timeline slips, and beta in the group remains high enough to justify paired exposure.